PDSB Loss Improves as Costs Drop
PDS Biotechnology (NASDAQ:PDSB), a clinical-stage immunotherapy company focused on innovative oncology and infectious disease solutions, released its second quarter results on August 13, 2025, for the period ending June 30. The most significant news was a $0.02 per share beat on net loss (GAAP) versus analyst expectations, as net loss per share (GAAP) came in at ($0.21) against an estimated ($0.23). No revenue was reported, which aligns with the company's pre-commercial status. Total operating expenses (GAAP) declined to $7.6 million, compared to $8.7 million for the three months ended June 30, 2024. Persistent operating losses and increasing interest expense added financial pressure, but the period was notable for progress in core clinical trials, particularly in the Versamune® HPV and PDS01ADC programs. Overall, the quarter demonstrated disciplined spending, ongoing advancement across clinical assets, and highlighted financial headwinds with a shrinking cash position.
Source: Analyst estimates for the quarter provided by FactSet.
PDS Biotechnology develops immunotherapies using its proprietary technology platforms, Versamune® and Infectimune®. Versamune® is designed to boost the immune system's ability to detect and destroy cancer cells. Infectimune® enhances immune responses against infectious diseases, aiming to overcome critical shortcomings of existing vaccine and immunotherapy options.
Source Fool.com
